Innovest Global, Inc. Stock Symbol IVST is a
Public diversified Holding company that is already a ten-bagger (Up 1000% in
the market) this year with much more on the way based on fundamentals AND
technical from our research. Here's what we found:
Innovest Global, Inc. (OTC Markets: IVST) is
fundamentally in the Conglomerates industry. IVST is a diversified holding
company with operations in commercial and industrial products and services,
energy, biotechnology, and health services. The primary growth strategy of IVST
is to acquire niche, high-growth businesses that are capable of generating
significant annual revenue and that fit with other subsidiaries in their
divisions. Planned subsidiaries operate across telehealth, biotech, building
materials, commercial energy, business-to-business distribution, national call
center and auto sales. Since January IVST has acquired 5 companies and those
subsidiaries have grown in revenue 50% post acquisition. That means that when IVST
buys a company, that company grows after the acquisition exponentially.
Based out of Cleveland, Ohio, IVST is
easily one of the better fundamental companies trading on the OTC marketplace
and in fact is Ohios fastest growing publicly traded company. Innovest
Global, Inc. is already up 10-fold in 2018 after starting off in Jan
around $0.02. Since then the stock hit a YTD all-time high of $0.55 in March
2018 it has since settled into a strong support around .23-.25. IVST continues
to hold onto the substantial gains thus far and from our estimates is ready for
the next leg, which we hope will be into the .50 range. Based upon the
companys strong fundamental AND technical picture, Innovest Global,
Inc. could easily retake its all-time high by the end of 2018.
What a stock structure IVST has
folks! The company has an amazing unchanged free-trading float of 11,796,710
common shares with no convertible debts, no warrants
or options outstanding, and employs 45.
Onto the meat and potatoes:
IVST owns 20% of StemVax Therapeutics, which happens
to be the first company in its Biotech Division.
StemVax Therapeutics is a Translational Biotechnology Company
that develops novel therapies for brain tumor patients. We focus our efforts on
developing immunotherapeutic approaches to treating patients with Glioblastoma
Multiforme (GBM), a devastating brain cancer. We also focus our research
efforts on novel drug development to target Cancer Stem cells and other
multi-resistant cancer cells. Lead by world-renowned neuroscientist, Dr. Dwain
Morris-Irvin, the Biotech & Health Sciences Division is currently focused
on commercializing StemVaxs cancer vaccination therapy
technology. The cancer vaccination therapy technology was just recently awarded
a U.S. patent! We seek to make a difference in patients lives bringing new
beginnings to the market by developing novel therapeutics.
IVSTs management team has been extremely busy with its pending
mega-acquisition of a building materials company, which produces $30
million in annual revenues! Once the building materials company is
acquired, it will serve as Innovest Globals third division.
The initial discussions began back in March 2018, followed by formal
negotiations in April 2018. In June, Innovest management
formally proposed the acquisition pitch to the target companys board of
directors. Upon conclusion of the presentation, both parties had signed and
executed a Letter of Intent (LOI) document. In late August 2018, it was
announced that both parties have effectively reached an agreement on the
acquisition transaction structure and long form documents. We expect this to
formally close at any moment.
IVST has the vision and model of Berkshire-Hathaway; we look
forward to its evolution!